{"id":"https://openalex.org/W4380894484","doi":"https://doi.org/10.1016/j.japh.2023.06.010","title":"Independent community pharmacists\u2019 attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder","display_name":"Independent community pharmacists\u2019 attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder","publication_year":2023,"publication_date":"2023-06-16","ids":{"openalex":"https://openalex.org/W4380894484","doi":"https://doi.org/10.1016/j.japh.2023.06.010","pmid":"https://pubmed.ncbi.nlm.nih.gov/37331654"},"language":"en","primary_location":{"id":"doi:10.1016/j.japh.2023.06.010","doi":"https://doi.org/10.1016/j.japh.2023.06.010","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.japh.2023.06.010","pdf_url":null,"source":{"id":"https://openalex.org/S4210228861","display_name":"Journal of the American Pharmacists Association","issn_l":"1544-3191","issn":["1544-3191","1544-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","medline","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Pharmacists Association","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012255633","display_name":"Rana Zalmai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I86519309","display_name":"The University of Texas at Austin","ror":"https://ror.org/00hj54h04","country_code":"US","type":"education","lineage":["https://openalex.org/I86519309"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rana Zalmai","raw_affiliation_strings":["College of Pharmacy, The University of Texas at Austin, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Pharmacy, The University of Texas at Austin, Austin, TX","institution_ids":["https://openalex.org/I86519309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019098919","display_name":"Lucas G. Hill","orcid":"https://orcid.org/0000-0001-5958-0159","observed_orcids":["https://orcid.org/0000-0001-5958-0159"]},"institutions":[{"id":"https://openalex.org/I86519309","display_name":"The University of Texas at Austin","ror":"https://ror.org/00hj54h04","country_code":"US","type":"education","lineage":["https://openalex.org/I86519309"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucas G. Hill","raw_affiliation_strings":["College of Pharmacy, The University of Texas at Austin, Austin, TX"],"raw_orcid":"https://orcid.org/0000-0001-5958-0159","affiliations":[{"raw_affiliation_string":"College of Pharmacy, The University of Texas at Austin, Austin, TX","institution_ids":["https://openalex.org/I86519309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047120925","display_name":"Lindsey J. Loera","orcid":"https://orcid.org/0000-0002-7969-5209","observed_orcids":["https://orcid.org/0000-0002-7969-5209"]},"institutions":[{"id":"https://openalex.org/I86519309","display_name":"The University of Texas at Austin","ror":"https://ror.org/00hj54h04","country_code":"US","type":"education","lineage":["https://openalex.org/I86519309"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lindsey J. Loera","raw_affiliation_strings":["College of Pharmacy, The University of Texas at Austin, Austin, TX"],"raw_orcid":"https://orcid.org/0000-0002-7969-5209","affiliations":[{"raw_affiliation_string":"College of Pharmacy, The University of Texas at Austin, Austin, TX","institution_ids":["https://openalex.org/I86519309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092184924","display_name":"Quinn Mosgrove","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I86519309","display_name":"The University of Texas at Austin","ror":"https://ror.org/00hj54h04","country_code":"US","type":"education","lineage":["https://openalex.org/I86519309"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Quinn Mosgrove","raw_affiliation_strings":["College of Pharmacy, The University of Texas at Austin, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Pharmacy, The University of Texas at Austin, Austin, TX","institution_ids":["https://openalex.org/I86519309"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071664431","display_name":"Carolyn M. Brown","orcid":"https://orcid.org/0000-0002-6976-7686","observed_orcids":["https://orcid.org/0000-0002-6976-7686"]},"institutions":[{"id":"https://openalex.org/I86519309","display_name":"The University of Texas at Austin","ror":"https://ror.org/00hj54h04","country_code":"US","type":"education","lineage":["https://openalex.org/I86519309"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carolyn Brown","raw_affiliation_strings":["College of Pharmacy, The University of Texas at Austin, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Pharmacy, The University of Texas at Austin, Austin, TX","institution_ids":["https://openalex.org/I86519309"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5012255633"],"corresponding_institution_ids":["https://openalex.org/I86519309"],"apc_list":{"value":2630,"currency":"USD","value_usd":2630},"apc_paid":null,"fwci":3.8218,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.9370185,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":99},"biblio":{"volume":"63","issue":"5","first_page":"1558","last_page":"1565.e4"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13970","display_name":"Pharmacy and Medical Practices","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/buprenorphine-naloxone","display_name":"buprenorphine/naloxone","score":0.9490000009536743},{"id":"https://openalex.org/keywords/opioid-use-disorder","display_name":"opioid use disorder","score":0.9990000128746033},{"id":"https://openalex.org/keywords/community-pharmacists","display_name":"community pharmacists","score":0.9070000052452087},{"id":"https://openalex.org/keywords/pharmacists-attitudes","display_name":"pharmacist attitudes","score":0.8339999914169312},{"id":"https://openalex.org/keywords/theory-of-planned-behavior","display_name":"theory of planned behavior","score":0.9430000185966492},{"id":"https://openalex.org/keywords/opioid-prescribing","display_name":"opioid prescribing","score":0.4480000138282776},{"id":"https://openalex.org/keywords/reimbursement","display_name":"reimbursement","score":0.7020000219345093},{"id":"https://openalex.org/keywords/rural-and-underserved-populations","display_name":"rural and underserved populations","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7627222537994385},{"id":"https://openalex.org/C2778949969","wikidata":"https://www.wikidata.org/wiki/Q407721","display_name":"Buprenorphine","level":4,"score":0.6623126864433289},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6308128237724304},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.5910703539848328},{"id":"https://openalex.org/C2779418921","wikidata":"https://www.wikidata.org/wiki/Q1639178","display_name":"Opioid use disorder","level":4,"score":0.569929301738739},{"id":"https://openalex.org/C2778750930","wikidata":"https://www.wikidata.org/wiki/Q4540629","display_name":"(+)-Naloxone","level":4,"score":0.552656888961792},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.5456687211990356},{"id":"https://openalex.org/C2780084366","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demographics","level":2,"score":0.5041936635971069},{"id":"https://openalex.org/C2779703844","wikidata":"https://www.wikidata.org/wiki/Q760125","display_name":"Reimbursement","level":3,"score":0.466813325881958},{"id":"https://openalex.org/C2994493120","wikidata":"https://www.wikidata.org/wiki/Q13107184","display_name":"Community pharmacy","level":3,"score":0.44551610946655273},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.34863001108169556},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.2632676064968109},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.19099074602127075},{"id":"https://openalex.org/C149923435","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demography","level":1,"score":0.17474395036697388},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.1692863404750824},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.09863105416297913},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009293","descriptor_name":"Opioid-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010595","descriptor_name":"Pharmacists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D033182","descriptor_name":"Intention","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.japh.2023.06.010","doi":"https://doi.org/10.1016/j.japh.2023.06.010","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.japh.2023.06.010","pdf_url":null,"source":{"id":"https://openalex.org/S4210228861","display_name":"Journal of the American Pharmacists Association","issn_l":"1544-3191","issn":["1544-3191","1544-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","medline","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Pharmacists Association","raw_type":"journal-article"},{"id":"pmid:37331654","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37331654","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Pharmacists Association : JAPhA","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G808848946","display_name":null,"funder_award_id":"1H79TI083288","funder_id":"https://openalex.org/F4320332164","funder_display_name":"Substance Abuse and Mental Health Services Administration"},{"id":"https://openalex.org/G8722368734","display_name":"Texas Targeted Opioid Response - SOR22 TI-22-05","funder_award_id":"H79TI085747","funder_id":"https://openalex.org/F4320332164","funder_display_name":"Substance Abuse and Mental Health Services Administration"}],"funders":[{"id":"https://openalex.org/F4320308137","display_name":"Texas Health and Human Services Commission","ror":"https://ror.org/01yf9rd65"},{"id":"https://openalex.org/F4320332164","display_name":"Substance Abuse and Mental Health Services Administration","ror":"https://ror.org/03t3qg659"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W1500042416","https://openalex.org/W1698707290","https://openalex.org/W1994454457","https://openalex.org/W2004537220","https://openalex.org/W2008587268","https://openalex.org/W2013122535","https://openalex.org/W2063201122","https://openalex.org/W2099697766","https://openalex.org/W2120892009","https://openalex.org/W2132253094","https://openalex.org/W2171737529","https://openalex.org/W2471133257","https://openalex.org/W2582897974","https://openalex.org/W2750641163","https://openalex.org/W2801514601","https://openalex.org/W2801991165","https://openalex.org/W2808907017","https://openalex.org/W2896562901","https://openalex.org/W2944783824","https://openalex.org/W2972341277","https://openalex.org/W2994589854","https://openalex.org/W3000270431","https://openalex.org/W3005454586","https://openalex.org/W3013516348","https://openalex.org/W3089525935","https://openalex.org/W3096025577","https://openalex.org/W3096940405","https://openalex.org/W3105198263","https://openalex.org/W3142635572","https://openalex.org/W3157558970","https://openalex.org/W3164660988","https://openalex.org/W3165633131","https://openalex.org/W3204310245","https://openalex.org/W3205115907","https://openalex.org/W3209276891","https://openalex.org/W4225154717","https://openalex.org/W4280546789","https://openalex.org/W4281922102","https://openalex.org/W4283696989","https://openalex.org/W4292554410","https://openalex.org/W4292866823","https://openalex.org/W4293792756","https://openalex.org/W4294675167","https://openalex.org/W4295007502","https://openalex.org/W4309466630"],"related_works":["https://openalex.org/W4292866823","https://openalex.org/W2968104968","https://openalex.org/W4318912016","https://openalex.org/W7221067421","https://openalex.org/W2120892009","https://openalex.org/W4225154717","https://openalex.org/W2990821241","https://openalex.org/W4386143193","https://openalex.org/W4285678705","https://openalex.org/W4405847172"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-06-17T00:00:00"}